January 1, 2014 | The Israeli company listed on NASDAQ NeuroDerm saw its share price doubled following the announcement of results from a Parkinson’s drug trial. According to the company, a mid-stage study showed that giving patients a higher dose of its Parkinson’s drug could allow them to avoid surgery in certain cases. NeuroDerm’s Parkinson’s medication is delivered through a waist-worn pump as compared to other methods delivered orally. As a result of the study’s conclusions, NeuroDerm’s share price doubled, reaching a record high of $14.12 and giving the company a market valuation of $231 million.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

Israeli Tech Deters Distracted Drivers In New Italian Pilot
November 28, 2023

German Health Firm Enlists Israeli 3D Printer To Boost CT Imaging
November 28, 2023

Biotech Firm Unveils New Inflammatory Disease, Cancer Therapy
November 27, 2023

Global Money Transfer Firm Brings In Israeli AI Financial Watchdog
November 27, 2023
Facebook comments